ID   Rh18
AC   CVCL_1659
AS   CVCL_5918
SY   RH18; RH-18; Rh-18; Rh 18; SJRH-18; SJRH18
DR   BTO; BTO:0005380
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473565
DR   BioSample; SAMN10989566
DR   cancercelllines; CVCL_1659
DR   Cell_Model_Passport; SIDM00454
DR   ChEMBL-Cells; CHEMBL3308533
DR   ChEMBL-Targets; CHEMBL2366350
DR   Cosmic; 687954
DR   Cosmic; 801757
DR   Cosmic; 802046
DR   Cosmic; 971774
DR   Cosmic; 1037296
DR   Cosmic; 1048109
DR   Cosmic; 1097747
DR   Cosmic; 1104560
DR   Cosmic; 1108739
DR   Cosmic; 1509196
DR   Cosmic; 1620037
DR   Cosmic-CLP; 971774
DR   DepMap; ACH-000689
DR   DSMZ; ACC-491
DR   DSMZCellDive; ACC-491
DR   EGA; EGAS00001000978
DR   GDSC; 971774
DR   GEO; GSM219745
DR   GEO; GSM1670377
DR   GEO; GSM1676325
DR   GEO; GSM1701658
DR   IARC_TP53; 24981
DR   IARC_TP53; 27702
DR   LiGeA; CCLE_325
DR   PharmacoDB; RH18_1311_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1659
DR   Wikidata; Q54950333
RX   CelloPub=CLPUB00569;
RX   PubMed=3607778;
RX   PubMed=6950170;
RX   PubMed=7536457;
RX   PubMed=8275086;
RX   PubMed=8383879;
RX   PubMed=9802058;
RX   PubMed=9823299;
RX   PubMed=11051265;
RX   PubMed=19235922;
RX   PubMed=20164919;
RX   PubMed=20922763;
RX   PubMed=23578105;
RX   PubMed=23882450;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32758582;
RX   PubMed=35839778;
WW   https://www.cccells.org/PDF_Files/Rhabdomyosarcoma/Rh18%20Cell%20Line%20Data%20Sheet.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-557.html
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: African American.
CC   Characteristics: Established from a immuno-deficient mice xenograft (HxRh18).
CC   Doubling time: 57.8 hours (PubMed=3607778); 83 hours (PubMed=20922763); ~60-70 hours (DSMZ=ACC-491); 65 hours (COG).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086; PubMed=23578105).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=74.53%; Native American=0.16%; East Asian, North=4.19%; East Asian, South=0%; South Asian=0%; European, North=5.05%; European, South=16.06% (PubMed=30894373).
CC   Derived from site: In situ; Perineus, muscle; UBERON=UBERON_0002379.
ST   Source(s): COG; Cosmic-CLP; DSMZ; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 9,12
ST   D18S51: 16,17
ST   D19S433: 12,14
ST   D21S11: 32.2,33.2
ST   D2S1338: 19,24
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   FGA: 23
ST   Penta D: 7,12
ST   Penta E: 8,13
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 15,17
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   CelloPub=CLPUB00569;
RA   Dickman P.S., Tsokos M.G., Triche T.J.;
RT   "Biology of rhabdomyosarcoma: cell culture, xenografts, and animal
RT   models.";
RL   (In) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton (1991).
//
RX   PubMed=3607778;
RA   Hazelton B.J., Houghton J.A., Parham D.M., Douglass E.C.,
RA   Torrance P.M., Holt H., Houghton P.J.;
RT   "Characterization of cell lines derived from xenografts of childhood
RT   rhabdomyosarcoma.";
RL   Cancer Res. 47:4501-4507(1987).
//
RX   PubMed=6950170; DOI=10.1093/jnci/68.3.437;
RA   Houghton J.A., Houghton P.J., Webber B.L.;
RT   "Growth and characterization of childhood rhabdomyosarcomas as
RT   xenografts.";
RL   J. Natl. Cancer Inst. 68:437-443(1982).
//
RX   PubMed=7536457; DOI=10.1002/gcc.2870120305;
RA   Biegel J.A., Nycum L.M., Valentine V., Barr F.G., Shapiro D.N.;
RT   "Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar
RT   rhabdomyosarcoma by fluorescence in situ hybridization.";
RL   Genes Chromosomes Cancer 12:186-192(1995).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8383879; DOI=10.1126/science.8383879;
RA   Tapscott S.J., Thayer M.J., Weintraub H.M.;
RT   "Deficiency in rhabdomyosarcomas of a factor required for MyoD
RT   activity and myogenesis.";
RL   Science 259:1450-1453(1993).
//
RX   PubMed=9802058;
RA   McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A.,
RA   Harris L.C.;
RT   "Bax is an important determinant of chemosensitivity in pediatric
RT   tumor cell lines independent of Bcl-2 expression and p53 status.";
RL   Oncol. Res. 10:235-244(1998).
//
RX   PubMed=9823299;
RA   Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T.,
RA   Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.;
RT   "Gene expression profiling of alveolar rhabdomyosarcoma with cDNA
RT   microarrays.";
RL   Cancer Res. 58:5009-5013(1998).
//
RX   PubMed=11051265;
RA   Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.;
RT   "Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced
RT   apoptosis and highly sensitive to TRAIL-induced apoptosis.";
RL   Clin. Cancer Res. 6:4119-4127(2000).
//
RX   PubMed=19235922; DOI=10.1002/gcc.20655;
RA   Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C.,
RA   Koster J., Summersgill B.M., Messahel B., Versteeg R.,
RA   Pritchard-Jones K., Kool M., Shipley J.M.;
RT   "Genomic imbalances in rhabdomyosarcoma cell lines affect expression
RT   of genes frequently altered in primary tumors: an approach to identify
RT   candidate genes involved in tumor development.";
RL   Genes Chromosomes Cancer 48:455-467(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=23578105; DOI=10.1111/cas.12173;
RA   Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R.,
RA   Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y.,
RA   Ogawa S.;
RT   "Characterization of genetic lesions in rhabdomyosarcoma using a
RT   high-density single nucleotide polymorphism array.";
RL   Cancer Sci. 104:856-864(2013).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32758582; DOI=10.1016/j.gene.2020.145025;
RA   Batchu S., Kellish A.S., Hakim A.A.;
RT   "Assessing alveolar rhabdomyosarcoma cell lines as tumor models by
RT   comparison of mRNA expression profiles.";
RL   Gene 760:145025.1-145025.5(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//